GSK’s vaccine for respiratory syncytial virus (RSV) has gained the support of a key panel of US regulatory advisers for use in people aged 60 and older. The vaccine was found to be effective and safe, according to the panel of 12 outside advisers to the Food and Drug Administration. The move puts GSK in competition with Pfizer to bring the first vaccine for RSV to the US market. The RSV vaccine market for adults could be worth up to $10 billion by 2032, according to Bloomberg Intelligence projections.
#RSVvaccine #GSK #OlderAdults #PublicHealth
Read this amazing article from Source link
Does the FDA panel support GSK’s RSV vaccine for older individuals?
